Novartis

Fabrikstrasse 2, 4056 Basel
Novartis   link
Location: Basel
Discipline: Pharmacology
Related:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

#display_name

Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Pharmacology - Health - Mar 28
Patients & Caregivers Healthcare Professionals Society & ESG Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months 1 -   Prespecified exploratory analysis based on safety reporting from the three trials, showed fewe
Pharmacology - Health - Mar 27

Novartis Cosentyx gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum

Patients & Caregivers Healthcare Professionals Society & ESG - EMA CHMP positive opinion in non-radiographic axial spondyloarthritis (nr-axSpA) paves way for fourth indication in Europe, and is based on Phase III PREVENT data 1 -   If approved, Cosentyx would become the first fully-human IL

Pharmacology - Business - Mar 26

Novartis and Life Sciences Companies Commit Expertise and Assets to the Fight Against COVID-19 Pandemic alongside Bill & Melinda Gates Foundation

Patients & Caregivers Healthcare Professionals Society & ESG - Collaboration to address product development and scale up challenges posed by current pandemic   Basel, March 26, 2020 - Today, Novartis and a consortium of life sciences companies announced an important collaboration to acceler

Pharmacology - Health - Mar 24

Zolgensma data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing

Patients & Caregivers Healthcare Professionals Society & ESG Interim SPR1NT data showed presymptomatic babies with SMA treated with Zolgensma (onasemnogene abeparvovec-xioi) soon after birth achieved age-appropriate motor milestones -   In addition to meeting both co-primary efficacy endp

Pharmacology - Health - Mar 19

Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma the only gene therapy for patients with spinal muscular atrophy (SMA)

Patients & Caregivers Healthcare Professionals Society & ESG - Zolgensma (onasemnogene abeparvovec), a one-time administered gene therapy, is approved for the treatment of SMA in patients under the age of two, including those who are pre-symptomatic at diagnosis -   Zolgensma has demonstrat

Pharmacology - Health - Mar 27

AveXis receives positive CHMP opinion for Zolgensma , the only gene therapy for spinal muscular atrophy (SMA)

Patients & Caregivers Healthcare Professionals Society & ESG - Zolgensma (onasemnogene abeparvovec), a one-time administered gene therapy, has been recommended for European Commission (EC) conditional approval for patients with spinal muscular atrophy (SMA) and a clinical diagnosis of Type

Pharmacology - Health - Mar 24

AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2

Patients & Caregivers Healthcare Professionals Society & ESG - SMA Type 2 patients between two and five years of age who received Dose B met the primary efficacy endpoint with a remarkable mean increase of 6.0 points in HFMSE scores from baseline to month 12, twice the clinically mea

Pharmacology - Health - Mar 20

Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response

Patients & Caregivers Healthcare Professionals Society & ESG - Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19.

Pharmacology - Health - Mar 18

Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy

Patients & Caregivers Healthcare Professionals Society & ESG Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalents and heterozygous

» More news


Job Offers

» Job Offer: Novartis

Last job offers


Website Preview

Link

Medicine and Life Sciences